The Center for Biosimilars® recaps the top stories for the week of December 30, 2019.
Transcript
Hi, I’m Christina Mattina for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of December 30, 2019.
Number 5: A recent study concluded that, for patients who experienced side effects or a loss of response after switching to biosimilar infliximab, a switch back to the reference product was effective.
Number 4: Anti—tumor necrosis factor therapies could play a role in alleviating or even preventing some adverse events related to immune checkpoint inhibition.
Number 3: Recent research shows that many US patients with rheumatoid arthritis who do not respond well to conventional drugs are not advancing to biologic treatment.
Number 2: Clover Biopharmaceuticals announced this week that it has dosed the first patient in a phase 3 clinical study of a proposed etanercept biosimilar.
Number 1: An official working group of the Swiss Society of Gastroenterology has issued a new position statement on the use of biosimilars in treating inflammatory bowel disease.
To read all of these articles and more, visit centerforbiosimilars.com.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.